文献速递肝病消化道肿瘤与早癌

剪接外显子9缺失的ADRM1通过选择性降解抑癌蛋白FBXW7促进肝癌发生

Spliced exon9 ADRM1 promotes liver oncogenicity via selective degradation of tumor suppressor FBXW7.
PubMed 文献 · J Hepatol · 2025-01-07

研究在肝细胞癌(HCC)中发现外显子9跳跃剪接的ADRM1新变体ADRM1-ΔEx9,利用人肝类器官、流体动力学转染小鼠模型、患者来源肿瘤类器官及异种移植模型,揭示其通过选择性降解抑癌蛋白FBXW7促进肝癌形成,并与PARP抑制剂奥拉帕利存在合成致死关联。

要点

  • ADRM1-ΔEx9而非全长ADRM1赋予人肝类器官促生存优势,并在小鼠模型中导致更显著的肿瘤形成。
  • ADRM1-ΔEx9的C端缩短与不同去泛素化酶BAP1结合,改变蛋白酶体特异性;外显子8-10新融合为FBXW7创建新结合位点,介导其选择性蛋白酶体降解。
  • 表达ADRM1-ΔEx9的HCC肿瘤FBXW7蛋白缺失,对PARP抑制剂奥拉帕利敏感,呈剂量依赖性。

核心结论

  • ADRM1-ΔEx9重定向泛素蛋白酶体特异性,选择性降解抑癌蛋白FBXW7,促进HCC肿瘤形成,并提供PARP抑制剂治疗的合成致死关联。

研究设计与样本

  • 研究使用人肝来源非肿瘤类器官、流体动力学体内转染小鼠模型、患者来源肿瘤类器官及异种移植模型,并通过Proteome Profiler Human Ubiquitin Array阐明机制。

主要发现

  • ADRM1-ΔEx9而非全长ADRM1赋予人肝类器官促生存优势,并在流体动力学转染小鼠模型中导致更显著的肿瘤形成。
  • 功能敲低导致细胞系和患者来源类器官自发凋亡,凸显ADRM1-ΔEx9在HCC致癌性中的关键作用。
  • ADRM1-ΔEx9缩短的C端与不同去泛素化酶伙伴BAP1相互作用,改变蛋白酶体特异性;外显子8-10新融合为抑癌蛋白FBXW7创建新结合位点,导致其选择性蛋白酶体介导的降解。
  • 表达ADRM1-ΔEx9的肿瘤中FBXW7蛋白缺失,凸显其对PARP抑制剂奥拉帕利的敏感性。
  • 原发HCC肿瘤中ADRM1-ΔEx9在部分患者中过表达,与较差生存相关,并与奥拉帕利存在合成致死关联的治疗机会窗口。

关键数值与推荐

  • 表达ADRM1-ΔEx9的HCC肿瘤对奥拉帕利敏感,呈剂量依赖性。

临床怎么用

  • 作者认为,ADRM1-ΔEx9表达提示HCC患者可能对奥拉帕利治疗存在合成致死关联的治疗机会窗口。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The ubiquitin receptor ADRM1/Rpn13 governs the specificity of eukaryotic protein degradation. We first discovered a novel spliced variant of ADRM1 with a skipped exon 9, termed ADRM1-ΔEx9, in human hepatocellular carcinoma (HCC) by SMRT sequencing. The aim of this study was to elucidate this novel ubiquitin receptor's underlying biology and clinical implications in HCC. METHODS: The role of ADRM1-ΔEx9 in early liver carcinogenesis was studied using human liver-derived non-tumoral organoids and a murine model with hydrodynamic in vivo transfection. ADRM1-ΔEx9 biology in HCC and its potential as a biomarker for predicting olaparib response were investigated using patient-derived tumor organoids and xenograft models. The underlying mechanism was delineated using the Proteome Profiler Human Ubiquitin Array. RESULTS: ADRM1-ΔEx9, not its full-length counterpart, conferred human liver organoids with pro-survival advantages and led to more profound tumor formation in a hydrodynamic transfected murine model. Functional knockdown resulted in spontaneous apoptosis in cell lines and patient-derived organoids, highlighting a pivotal role for ADRM1-ΔEx9 in HCC oncogenicity. Mechanistically, the shortened C-terminus of ADRM1-ΔEx9 interacted with a different deubiquitinase partner (BAP1) to alter proteasome specificity. The new exon 8-10 fusion in ADRM1-ΔEx9 creates a de novo binding site for the tumor suppressor protein FBXW7, resulting in its selective proteasome-mediated degradation. The loss of FBXW7 protein in ADRM1-ΔEx9-expressing tumors underscores their sensitivity to the PARP inhibitor olaparib. Notably, findings on ADRM1-ΔEx9 in primary HCC tumors denote its overexpression in a subgroup of patients with inferior survival and a window of therapeutic opportunity through a synthetic lethal association with olaparib. CONCLUSION: ADRM1-ΔEx9 redirects ubiquitin proteasome specificity to selectively degrade the tumor suppressor protein FBXW7. This promotes HCC tumor formation and provides a synthetic lethal link for PARP inhibitor therapy. IMPACT AND IMPLICATIONS: Reduced tumor suppressor protein FBXW7 expression is pivotal in hepatocellular carcinoma (HCC) pathogenesis and other liver diseases. However, the regulatory mechanism governing FBXW7 protein expression remains elusive. Herein, we unveil a non-canonical spliced isoform of the ubiquitin receptor ADRM1 that selectively degrades FBXW7 protein, thereby promoting the premalignant transformation of hepatic cells and conferring growth advantages to HCC tumors. Furthermore, our results demonstrate that ADRM1-ΔEx9-expressing HCC tumors exhibited sensitivity to olaparib in a dose-dependent manner, implicating the potential use of olaparib in targeting ADRM1-ΔEx9-driven HCC growth.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Sun Y, Xu M, Wan HL, et al. Spliced exon9 ADRM1 promotes liver oncogenicity via selective degradation of tumor suppressor FBXW7. J Hepatol. 2025. PMID: 39788431. doi:10.1016/j.jhep.2024.12.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。